1 completed, 1 recruiting, 1 suspended. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 1, Recruiting 1, Suspended 1 |
| Phase 2 | 1 | Suspended 1 |
Follow DT2216: new trials by email Literature Review of DT2216 trials Research Report on DT2216
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer DT2216, Paclitaxel - Ovarian Cancer, Ovarian Carcinoma | Phase 1 | Recruiting | Elizabeth Stover, MD, PhD | 30 | 2025-09-22 | 2026-09-11 |
| Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma Bcl-XL Proteolysis Targeting Chimera DT2216, Biospecimen Collection, Irinotecan - Childhood Fibrolamellar Carcinoma, Recurrent Childhood Fibrolamellar Carcinoma | Phase 1 / Phase 2 | Suspended | Children's Oncology Group | 81 | 2025-06-12 | 2026-08-24 |
| A Study of DT2216 in Relapsed/Refractory Malignancies DT2216 - Solid Tumor, Hematologic Malignancy | Phase 1 | Completed | Dialectic Therapeutics, Inc | 20 | 2021-08-25 | 2025-04-16 |
Fibrolamellar hepatocellular carcinoma (1) · Hematologic Neoplasms (1) · Ovarian Neoplasms (1)
Children's Oncology Group (1) · Dialectic Therapeutics, Inc (1) · Elizabeth Stover, MD, PhD (1)
United States (3)
Elizabeth Stover, MD, PhD (1) · Michael Kurman, MD (1) · Michael V Ortiz (1)
UM1CA228823 (1)